A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125μg/mL to latanoprost 50μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

BMC Ophthalmology

Volumn 12, Issue 1, 2012, Pages

  Eveleth, David ^a   Starita, Carla ^b   Tressler, Charles ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; EYE DROPS; LATANOPROST; PROSTAGLANDIN F;

ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; DRUG TOLERANCE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MULTICENTER STUDY; OCULOPLETHYSMOGRAPHY; OPEN ANGLE GLAUCOMA; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; TONOMETRY, OCULAR;

EID: 84861163334     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-12-9     Document Type: Article

References (25)

1. Predictive factors of the optic nerve head for development or progression of glaucomatous visual field loss. Jonas JB, Martus P, Horn FK, Junemann A, Korth M, Budde WM, Invest Ophthalmol Vis Sci 2004 45 8 2613 2618 10.1167/iovs.03-1274 15277484 (Pubitemid 38998857)
2. Primary open-angle glaucoma. Weinreb RN, Khaw PT, Lancet 2004 363 9422 1711 1720 10.1016/S0140-6736(04)16257-0 15158634 (Pubitemid 38670330)
3. The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000 130 4 429 440 11024415
4. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, for the Early Manifest Glaucoma Trial Group, Arch Ophthalmol 2002 120 10 1268 1279 12365904 (Pubitemid 36105431)
5. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK II, Wilson MR, Gordon MO, for the Ocular Hypertension Treatment Study Group, Arch Ophthalmol 2002 120 6 701 713 12049574 (Pubitemid 34620348)
6. The influence of Latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study. Dinslage S, Hueber A, Diestelhorst M, Krieglstein GK, Graefes Arch Clin Exp Ophthalmol 2004 242 8 654 660 10.1007/s00417-003-0835-1 15241610 (Pubitemid 39242840)
7. Aqueous humor dynamics in ocular hypertensive patients. Toris CB, Koepsell SA, Yablonski ME, Camras CB, J Glaucoma 2002 11 3 253 258 10.1097/00061198-200206000-00015 12140404 (Pubitemid 34620103)
8. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH, Ophthalmology 2008 115 5 790 795 e794 10.1016/j.ophtha.2007.07.002 18452763 (Pubitemid 351602291)
9. Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6weeks of treatment. Johnson TV, Fan S, Zhan G, Camras CB, Toris CB, J Glaucoma 2010 19 6 356 364 10.1097/IJG.0b013e3181d12dd8 20179619
10. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Toris CB, Gabelt BT, Kaufman PL, Surv Ophthalmol 2008 53 Suppl 1 107 S120 19038618
11. Effects of prostaglandins on the aqueous humor outflow pathways. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL, Surv Ophthalmol 2002 47 Suppl 1 53 64 12204701
12. Initial clinical studies with prostaglandins and their analogues. Camras CB, Alm A, Surv Ophthalmol 1997 41 Suppl 2 61 68 9154278
13. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma. Hotehama Y, Mishima HK, Kitazawa Y, Masuda K, Jpn J Ophthalmol 1993 37 3 270 274 8295364 (Pubitemid 23320795)
14. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Alm A, Villumsen J, Tornquist P, Mandahl A, Airaksinen J, Tuulonen A, Marsk A, Resul B, Stjernschantz J, Ophthalmology 1993 100 9 1312 1316 discussion 1316-1317 8371917
15. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian latanoprost study group. Alm A, Stjernschantz J, Ophthalmology 1995 102 12 1743 1752 9098273 (Pubitemid 26004426)
16. Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue. Diestelhorst M, Krieglstein GK, Lusky M, Nagasubramanian S, Surv Ophthalmol 1997 41 Suppl 2 77 81 9154280
17. A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension. Fristrom B, Nilsson SE, Br J Ophthalmol 1997 81 10 867 870 10.1136/bjo.81.10.867 9486028 (Pubitemid 27469969)
18. Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity? Linden C, Alm A, Curr Eye Res 1998 17 6 567 572 10.1080/02713689808951229 9663846 (Pubitemid 28288655)
19. The effect on intraocular pressure of latanoprost once or four times daily. Linden C, Alm A, Br J Ophthalmol 2001 85 10 1163 1166 10.1136/bjo.85.10.1163 11567957 (Pubitemid 32929537)
20. A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure. Lusky M, Ticho U, Glovinsky J, Weinberger D, Nesher R, Yassur Y, Melamed S, Ophthalmology 1997 104 10 1720 1724 9331215 (Pubitemid 28053475)
21. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J, Ophthalmology 1993 100 9 1305 1311 8371916 (Pubitemid 23274022)
22. Standardizing the measurement of intraocular pressure for clinical research. Guidelines from the eye care technology forum. Kass MA, Ophthalmology 1996 103 1 183 185 8628552 (Pubitemid 26046178)
23. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM, Am J Ophthalmol 2010 149 4 661 671 e661 10.1016/j.ajo.2009.12.003 20346780
24. Side effects associated with prostaglandin analog therapy. Alm A, Grierson I, Shields MB, Surv Ophthalmol 2008 53 Suppl 1 93 105 19038628
25. Prostaglandin analogues in the anterior eye: their pressure lowering action and side effects. Cracknell KP, Grierson I, Exp Eye Res 2009 88 4 786 791 10.1016/j.exer.2008.08.022 18930047